Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab for MRD-positive B-precursor acute lymphoblastic leukemia in adults
NL-OMON39852Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Nov 2012
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Amgen. Primary endpoint: Complete MRD response after one cycle. Started Nov 2012; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NL-OMON39852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39852.